Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOTRICITY, INC.

(BTCY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Biotricity, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021

11/04/2021 | 03:47pm EST

Biotricity, Inc. reported earnings results for the second quarter and six months ended September 30, 2021. For the second quarter, the company reported sales was USD 1.81 million compared to USD 0.744585 million a year ago. Net loss was USD 10.75 million compared to USD 2.96 million a year ago. Basic loss per share from continuing operations was USD 0.256 compared to USD 0.085 a year ago. For the six months, sales was USD 3.57 million compared to USD 1.2 million a year ago. Net loss was USD 16.41 million compared to USD 6.12 million a year ago. Basic loss per share from continuing operations was USD 0.412 compared to USD 0.177 a year ago.


ę S&P Capital IQ 2021
All news about BIOTRICITY, INC.
2021BIOTRICITY INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financi..
AQ
2021Biotricity, Inc. Enters into Credit Agreement with SWK Funding LLC
CI
2021Biotricity Lists New Bioheart Monitoring Device on Amazon.com
MT
2021Health Care Stocks Firming Ahead of Monday's Close
MT
2021Health Care Stocks Posting Strong Gains
MT
2021Biotricity Completes $12M Debt Financing
MT
2021Biotricity Shares Rise 7.7% After Completing Debt Financing
DJ
2021Certain Common Stock of Biotricity, Inc. are subject to a Lock-Up Agreement Ending on 2..
CI
2021Certain Stock Options of Biotricity, Inc. are subject to a Lock-Up Agreement Ending on..
CI
2021Certain Warrants of Biotricity, Inc. are subject to a Lock-Up Agreement Ending on 25-DE..
CI
More news
Analyst Recommendations on BIOTRICITY, INC.
More recommendations
Financials (USD)
Sales 2022 9,29 M - -
Net income 2022 -39,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,44x
Yield 2022 -
Capitalization 158 M 158 M -
Capi. / Sales 2022 17,0x
Capi. / Sales 2023 5,46x
Nbr of Employees 44
Free-Float 78,5%
Chart BIOTRICITY, INC.
Duration : Period :
Biotricity, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 3,13 $
Average target price 6,50 $
Spread / Average Target 108%
EPS Revisions
Managers and Directors
Waqaas Al-Siddiq Chairman, President & Chief Executive Officer
John Ayanoglou Chief Financial Officer
Spencer LaDow Vice President-Engineering
Norman Murray Betts Independent Director
David A. Rosa Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIOTRICITY, INC.-21.36%154
THERMO FISHER SCIENTIFIC-11.56%233 816
DANAHER CORPORATION-12.76%205 105
INTUITIVE SURGICAL, INC.-18.32%104 835
SIEMENS HEALTHINEERS AG-9.69%75 669
EDWARDS LIFESCIENCES CORPORATION-10.34%72 523